These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2121038)

  • 21. Four-port bimanual 23-gauge vitrectomy for diabetic tractional retinal detachment.
    Wang ZY; Zhao KK; Li JK; Rossmiller B; Zhao PQ
    Acta Ophthalmol; 2016 Jun; 94(4):365-72. PubMed ID: 26855122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of the usefulness of vitrectomy in the treatment of proliferative diabetic retinopathy].
    Szymańska M
    Klin Oczna; 1992; 94(7-8):197-8. PubMed ID: 1300399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Removal of silicone oil following diabetic vitrectomy.
    Pearson RV; McLeod D; Gregor ZJ
    Br J Ophthalmol; 1993 Apr; 77(4):204-7. PubMed ID: 8494854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrinoid syndrome: a severe complication of vitrectomy surgery in diabetics.
    Sebestyen JG
    Ann Ophthalmol; 1982 Sep; 14(9):853-6. PubMed ID: 7181348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Vitrectomy in diabetic retinopathy: outcome, risk factors, complications].
    Helbig H; Kellner U; Bornfeld N; Foerster MH
    Klin Monbl Augenheilkd; 1998 May; 212(5):339-42. PubMed ID: 9677573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Timing of vitrectomy for proliferative diabetic retinopathy in cases with type II diabetes mellitus].
    Li X; Jiang Y; Ye C; Li C
    Zhonghua Yan Ke Za Zhi; 1999 Mar; 35(2):116-8. PubMed ID: 11835788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue plasminogen activator for the treatment of postoperative intraocular fibrinous membranes following cataract surgery.
    Schmitz K; Greite JH; Bartenschlager EM
    Ger J Ophthalmol; 1995 Mar; 4(2):75-9. PubMed ID: 7795512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of tissue plasminogen activator in postvitrectomy cases.
    Koutsandrea C; Apostolopoulos M; Theodossiadis P
    Int Ophthalmol; 1993 Apr; 17(2):95-100. PubMed ID: 8407122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of effectiveness of tissue plasminogen activator 20 or more days after vitrectomy.
    Folk JC; Hershey JM; Rivers MB
    Arch Ophthalmol; 1991 May; 109(5):614. PubMed ID: 1902660
    [No Abstract]   [Full Text] [Related]  

  • 30. Tractional elevations of the retina in patients with diabetes.
    Lincoff H; Serag Y; Chang S; Silverman R; Bondok B; el-Aswad M
    Am J Ophthalmol; 1992 Mar; 113(3):235-42. PubMed ID: 1543216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. En bloc perfluorodissection for tractional retinal detachment in proliferative diabetic retinopathy.
    Arevalo JF
    Ophthalmology; 2008 Jun; 115(6):e21-5. PubMed ID: 18423870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New viscodissection instrument for use with microincisional vitrectomy in the treatment of diabetic tractional retinal detachments.
    Fortun JA; Hubbard GB
    Arch Ophthalmol; 2011 Mar; 129(3):352-5. PubMed ID: 21402994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil.
    MacCumber MW; McCuen BW; Toth CA; Ferrone PJ; Jaffe GJ
    Ophthalmology; 1996 Feb; 103(2):269-73. PubMed ID: 8594513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes.
    Irvine WD; Johnson MW; Hernandez E; Olsen KR
    Arch Ophthalmol; 1991 May; 109(5):718-22. PubMed ID: 1902663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of tissue plasminogen activator in silicone oil-filled eyes.
    Kertes PJ; Peyman GA; Chou F; Meffert S; Conway MD
    Can J Ophthalmol; 1998 Feb; 33(1):28-9. PubMed ID: 9513769
    [No Abstract]   [Full Text] [Related]  

  • 36. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series.
    Yeoh J; Williams C; Allen P; Buttery R; Chiu D; Clark B; Essex R; McCombe M; Qureshi S; Campbell WG
    Clin Exp Ophthalmol; 2008 Jul; 36(5):449-54. PubMed ID: 18942219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [One year outcomes of pars plana vitrectomy in proliferative diabetic retinopathy].
    Tadera M; Kawamura H; Fujikawa M; Kakinoki M; Sawada T; Saishin Y; Ohji M
    Nippon Ganka Gakkai Zasshi; 2014 Jun; 118(6):502-7. PubMed ID: 25016792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transvitreal fibrinoid pseudoendophthalmitis after diabetic vitrectomy.
    Luo C; Ruby A; Neuwelt M; Williams GA
    Retina; 2013; 33(10):2069-74. PubMed ID: 23609127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm.
    Inoue M; Shiraga F; Shirakata Y; Morizane Y; Kimura S; Hirakata A
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1663-9. PubMed ID: 25418034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue plasminogen activator and penetrating keratoplasty.
    Heidemann DG; Williams GA; Blumenkranz MS
    Ophthalmic Surg; 1990 May; 21(5):364-5. PubMed ID: 2116614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.